Asthma is one of the common chronic diseases in children, and so far there is no cure for asthma. Asthma sufferers are estimated to be more than 300 million people worldwide, and the number of asthma treatments is growing every year. In recent years, thanks to advances in therapeutic medicines, asthma symptoms can now be successfully controlled with inhaled corticosteroids and, if necessary, in combination with bronchodilators. However, even with maximum use of these drugs, the effect may be insufficient, and there are still some patients with refractory asthma that are not adequately controlled with general treatment. Drugs called biologics may become a drug that works well for previously poorly treated asthma and is recently available in children with severe asthma. Three biologics are currently available for use in children: omalizumab, mepolizumab (6 years and older), and dupilumab (12 years and older). However, there is still a lack of clinical research evidence for the specific clinical improvement rate. Therefore, in this study, this paper conducted a literature review on the latest clinical trials of biological agents at home and abroad, summarized the clinical trials of common biological agents, and introduced the latest treatment methods. The differences and deficiencies between each other achieve the effect of enhancing the prevention and cognition of asthma.